DE60231804D1 - Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen - Google Patents
Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungenInfo
- Publication number
- DE60231804D1 DE60231804D1 DE60231804T DE60231804T DE60231804D1 DE 60231804 D1 DE60231804 D1 DE 60231804D1 DE 60231804 T DE60231804 T DE 60231804T DE 60231804 T DE60231804 T DE 60231804T DE 60231804 D1 DE60231804 D1 DE 60231804D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- iron
- homeostaste
- hepcidine
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 4
- 229940066919 hepcidin Drugs 0.000 title abstract 4
- 229910052742 iron Inorganic materials 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 3
- 102000018511 hepcidin Human genes 0.000 abstract 3
- 108060003558 hepcidin Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01401377 | 2001-05-25 | ||
| EP01401537A EP1262187A1 (en) | 2001-05-25 | 2001-06-14 | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| EP02290795 | 2002-03-29 | ||
| PCT/EP2002/006924 WO2002098444A2 (en) | 2001-05-25 | 2002-05-24 | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60231804D1 true DE60231804D1 (de) | 2009-05-14 |
Family
ID=27224392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60231804T Expired - Lifetime DE60231804D1 (de) | 2001-05-25 | 2002-05-24 | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7169758B2 (enExample) |
| EP (2) | EP2186524B1 (enExample) |
| JP (4) | JP4944360B2 (enExample) |
| CN (2) | CN101884780B (enExample) |
| AT (1) | ATE427114T1 (enExample) |
| AU (1) | AU2002321105A1 (enExample) |
| CA (1) | CA2448382C (enExample) |
| CY (1) | CY1120241T1 (enExample) |
| DE (1) | DE60231804D1 (enExample) |
| ES (2) | ES2326469T5 (enExample) |
| TR (1) | TR201806761T4 (enExample) |
| WO (1) | WO2002098444A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448382C (en) * | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| AU2003295644A1 (en) | 2002-11-19 | 2004-07-22 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US8017737B2 (en) | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| DE10349124A1 (de) | 2003-10-22 | 2005-05-19 | Roche Diagnostics Gmbh | Differenzialdiagnostik mit Hepcidin |
| US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
| KR100679100B1 (ko) * | 2004-10-29 | 2007-02-06 | 엘지.필립스 엘시디 주식회사 | 수평 전계 인가형 액정 표시 패널 및 그 제조방법 |
| US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| US8076306B2 (en) * | 2006-04-12 | 2011-12-13 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| MX2009000685A (es) * | 2006-07-21 | 2009-01-30 | Amgen Inc | Metodo para detectar y/o cuantificar hepcidina en una muestra. |
| WO2008036933A2 (en) * | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
| WO2008047485A1 (en) * | 2006-10-17 | 2008-04-24 | Naohisa Tomosugi | Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator |
| AR065083A1 (es) * | 2007-02-02 | 2009-05-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| WO2008124768A1 (en) | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| WO2008146903A1 (ja) * | 2007-05-31 | 2008-12-04 | Naohisa Tomosugi | 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法 |
| ES2385772T3 (es) | 2007-10-02 | 2012-07-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticuerpos específicos para la hepcidina humana |
| EP2201382A4 (en) | 2007-10-26 | 2011-01-26 | Univ Utah Res Found | IDENTIFICATION OF THE HEPCIDIN BINDING PLACE OF FERROPORTIN |
| CL2008003190A1 (es) * | 2007-11-02 | 2009-09-04 | Lilly Co Eli | Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica. |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| US8609817B2 (en) * | 2008-08-06 | 2013-12-17 | Eli Lilly And Company | Anti-hepcidin-25 selective antibodies and uses thereof |
| US20100068737A1 (en) * | 2008-09-16 | 2010-03-18 | University Of Tennessee Research Foundation | Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin |
| EP2349332B1 (en) * | 2008-11-13 | 2019-10-23 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| US8999935B2 (en) * | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
| DE102009034150A1 (de) | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| BR112012003701A2 (pt) | 2009-08-20 | 2019-09-24 | Vifor Int Ag | "novos antagonistas de quinolina-hepcidina" |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| BR112012005119A2 (pt) | 2009-09-07 | 2016-11-22 | Vifor Int Ag | novos antagonistas de hepcidina etanodiaminas |
| AR078278A1 (es) | 2009-09-09 | 2011-10-26 | Vifor Int Ag | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| US9228188B2 (en) | 2011-06-21 | 2016-01-05 | Alnylam Pharmaceuticals, Inc. | Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression |
| WO2013002354A1 (ja) * | 2011-06-29 | 2013-01-03 | 株式会社ダナフォーム | 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| EP2968503B1 (en) | 2013-03-15 | 2018-08-15 | Intrinsic LifeSciences LLC | Anti-hepcidin antibodies and uses thereof |
| EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| EP3203991A4 (en) | 2014-10-10 | 2018-06-20 | The Board of Regents of The University of Texas System | Hif-2 inhibitors for treating iron overload disorders |
| KR20180109917A (ko) * | 2016-01-08 | 2018-10-08 | 라 졸라 파마슈티칼 컴파니 | 헵시딘의 투여 방법 |
| WO2018165186A1 (en) * | 2017-03-07 | 2018-09-13 | Intrinsic Lifesciences Llc | Assessment of chronic iron deficiency |
| US20190315821A1 (en) * | 2018-02-23 | 2019-10-17 | La Jolla Pharmaceutical Company | Compositions comprising hepcidin and methods of use thereof |
| US12011489B2 (en) | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766207B1 (fr) * | 1997-07-11 | 2000-12-08 | Rhone Poulenc Agrochimie | Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies |
| FR2770853B1 (fr) * | 1997-11-07 | 1999-12-31 | Rhone Poulenc Agrochimie | Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies |
| US20030190669A1 (en) * | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000056879A1 (en) * | 1999-03-22 | 2000-09-28 | Universität Zürich | TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS |
| CA2448382C (en) * | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| US8017737B2 (en) † | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| AU2003295644A1 (en) † | 2002-11-19 | 2004-07-22 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| US7411048B2 (en) * | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| US7968091B2 (en) * | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| PL2061313T3 (pl) * | 2006-09-16 | 2014-01-31 | Soy Labs Llc | Zastosowanie peptydu sojowego (lunazyny) do obniżania poziomu cholesterolu całkowitego i ldl |
| AR065083A1 (es) † | 2007-02-02 | 2009-05-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| ES2385772T3 (es) † | 2007-10-02 | 2012-07-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticuerpos específicos para la hepcidina humana |
| WO2009097461A1 (en) | 2008-01-29 | 2009-08-06 | Neoguide Systems Inc. | Apparatus and methods for automatically controlling an endoscope |
| WO2010065815A2 (en) † | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| BR112014013697A2 (pt) | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| AU2015243990A1 (en) | 2014-04-07 | 2016-11-10 | La Jolla Pharmaceutical Company | Hepcidin mimetic peptides and uses thereof |
| WO2015200916A2 (en) | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
-
2002
- 2002-05-24 CA CA2448382A patent/CA2448382C/en not_active Expired - Lifetime
- 2002-05-24 AU AU2002321105A patent/AU2002321105A1/en not_active Abandoned
- 2002-05-24 ES ES02754742.1T patent/ES2326469T5/es not_active Expired - Lifetime
- 2002-05-24 DE DE60231804T patent/DE60231804D1/de not_active Expired - Lifetime
- 2002-05-24 CN CN201010232752.2A patent/CN101884780B/zh not_active Expired - Fee Related
- 2002-05-24 WO PCT/EP2002/006924 patent/WO2002098444A2/en not_active Ceased
- 2002-05-24 JP JP2003501483A patent/JP4944360B2/ja not_active Expired - Fee Related
- 2002-05-24 ES ES09004579.0T patent/ES2693050T3/es not_active Expired - Lifetime
- 2002-05-24 TR TR2018/06761T patent/TR201806761T4/en unknown
- 2002-05-24 US US10/478,987 patent/US7169758B2/en not_active Expired - Lifetime
- 2002-05-24 CN CN028148150A patent/CN1612746B/zh not_active Expired - Fee Related
- 2002-05-24 EP EP09004579.0A patent/EP2186524B1/en not_active Expired - Lifetime
- 2002-05-24 EP EP02754742.1A patent/EP1392345B2/en not_active Expired - Lifetime
- 2002-05-24 AT AT02754742T patent/ATE427114T1/de not_active IP Right Cessation
-
2006
- 2006-11-21 US US11/602,402 patent/US9234903B2/en not_active Expired - Fee Related
-
2009
- 2009-01-15 JP JP2009006614A patent/JP5717319B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-01 JP JP2011263858A patent/JP2012111755A/ja active Pending
-
2014
- 2014-04-24 JP JP2014090333A patent/JP5847231B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-23 US US14/747,926 patent/US9782453B2/en not_active Expired - Fee Related
-
2017
- 2017-08-09 US US15/672,616 patent/US10004784B2/en not_active Expired - Lifetime
-
2018
- 2018-05-18 CY CY20181100516T patent/CY1120241T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE427114T1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen | |
| DE60234269D1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| DE60026855D1 (de) | Synergistische kombination von roflumilast und salmeterol | |
| SE9800836D0 (sv) | New Compounds | |
| NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
| NO20034056D0 (no) | Proliferative sykdommer | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| DE60204966D1 (de) | Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis | |
| DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| WO2001058476A3 (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
| ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| DE60128009D1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent |